Cognition Therapeutics Inc CGTX
We take great care to ensure that the data presented and summarized in this overview for COGNITION THERAPEUTICS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CGTX
View all-
Pathstone Family Office, LLC Englewood, NJ2.21MShares$1.37 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.24MShares$770,3830.0% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL500KShares$310,0000.0% of portfolio
-
Geode Capital Management, LLC Boston, MA324KShares$200,6580.0% of portfolio
-
Cm Management, LLC250KShares$155,0000.1% of portfolio
-
American Financial Group Inc205KShares$127,1000.04% of portfolio
-
Ubs Group Ag198KShares$122,6720.0% of portfolio
-
Sigma Planning Corp Ann Arbor, MI197KShares$122,2570.0% of portfolio
-
Kestra Advisory Services, LLC188KShares$116,8290.0% of portfolio
-
Black Rock Inc. New York, NY153KShares$94,6000.0% of portfolio
Latest Institutional Activity in CGTX
Top Purchases
Top Sells
About CGTX
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
Insider Transactions at CGTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 07
2024
|
Aaron G.L. Fletcher Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,500
+36.96%
|
-
|
|
Jun 07
2024
|
Leslie W. Kreis Director |
BUY
Grant, award, or other acquisition
|
Indirect |
8,500
+36.96%
|
-
|
|
Jun 07
2024
|
Brett P Monia Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,500
+36.96%
|
-
|
|
Jun 07
2024
|
Ellen B Richstone Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,500
+25.76%
|
-
|
|
Jun 07
2024
|
Jack A. Khattar Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,500
+36.96%
|
-
|
|
Jun 07
2024
|
Peggy Wallace Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,500
+13.94%
|
-
|
|
May 01
2024
|
John Brendan Doyle Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,699
-6.7%
|
$8,699
$1.95 P/Share
|
|
Mar 14
2024
|
Lisa Ricciardi CEO & President |
BUY
Open market or private purchase
|
Direct |
5,700
+1.92%
|
$5,700
$1.75 P/Share
|
|
Feb 15
2024
|
Lisa Ricciardi CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+20.8%
|
-
|
|
Feb 15
2024
|
Anthony Caggiano Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+29.76%
|
-
|
|
Feb 15
2024
|
John Brendan Doyle Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+13.35%
|
-
|
|
Feb 03
2024
|
Lisa Ricciardi CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
27,828
-11.67%
|
$55,656
$2.29 P/Share
|
|
Feb 03
2024
|
Anthony Caggiano Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,777
-13.53%
|
$25,554
$2.29 P/Share
|
|
Nov 08
2023
|
Aaron G.L. Fletcher Director |
BUY
Grant, award, or other acquisition
|
Indirect |
500,095
+50.0%
|
$500,095
$1.05 P/Share
|
|
Nov 08
2023
|
Leslie W. Kreis Director |
BUY
Grant, award, or other acquisition
|
Indirect |
500,095
+50.0%
|
$500,095
$1.05 P/Share
|
|
Jun 09
2023
|
Aaron G.L. Fletcher Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+50.0%
|
-
|
|
Jun 09
2023
|
Leslie W. Kreis Director |
BUY
Grant, award, or other acquisition
|
Indirect |
6,000
+50.0%
|
-
|
|
Jun 09
2023
|
Jack A. Khattar Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+50.0%
|
-
|
|
Jun 09
2023
|
Ellen B Richstone Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+27.27%
|
-
|
|
Jun 09
2023
|
Peggy Wallace Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+12.01%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 206K shares |
|---|---|
| Open market or private purchase | 5.7K shares |
| Payment of exercise price or tax liability | 49.3K shares |
|---|